Japan Lifeline (7575.T) to acquire U.S.-based Cross Vascular after capital increase

Japan Lifeline agreed to buy Cross Vascular, via wholly owned subsidiary JLL Med USA, making it an indirect wholly owned unit. Deal values Cross Vascular common shares at USD 4,734,000, including USD 734,000 at closing and up to USD 4,000,000 earn-out. Advisory fees and related costs estimated at JPY 234 million, taking total estimated outlay to about JPY 977 million. Signing and closing are scheduled for Sept. 30, 2026. * JLL Med USA will inject USD 7,265,000 into Cross Vascular, lifting capital to USD 7,274,000 for debt payments, working capital. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JLL — Japan Lifeline Co. Ltd. published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein. (C)